Aeterna Zentaris Inc. (AEZS)
Dopo ore:
| Chiusura precedente | 4,9700 |
| Aperto | 5,0400 |
| Denaro | 4,8300 x 800 |
| Lettera | 4,9900 x 1400 |
| Min-Max giorno | 4,9300 - 5,0400 |
| Intervallo di 52 settimane | 0,1600 - 5,9000 |
| Volume | |
| Media Volume | 1.116.320 |
| Capitalizzazione | 24,231M |
| Beta (5 anni mensile) | 1,71 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,0790 |
| Prossima data utili | 02 nov 2022 - 07 nov 2022 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 28,00 |
- GlobeNewswire
Aeterna Zentaris Reports Second Quarter 2022 Financial Results and Recent Highlights
– Company ended the quarter with $58.2 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (Nasdaq: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the second quarter ended Jun
- GlobeNewswire
Aeterna Zentaris Announces Effective Date of Share Consolidation
TORONTO, ON, July 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that the Company has filed articles of amendment, to effect the previously announced share consolidation (or reverse stock split) (the “Consolidation”) of its issued and outstanding common shares (the “Common Shares”) on the basis of one post-Consolidati
- GlobeNewswire
Aeterna Zentaris Announces Shareholder Approval of Share Consolidation
TORONTO, ONTARIO, July 15, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that the proposed consolidation of the Company’s shares (the “Share Consolidation”) was approved at its reconvened annual meeting of shareholders (the “Meeting”) held today. Following the Meeting, the Company’s board
